Introduction

Methods
• Software for HIV-1 genotypic drug resistance testing is routinely used to generate clinical drug resistance interpretations. In this study we compare the differences found in the results obtained with 3 distinct software (Tab. 1).
• HIV sequencing data of forty five (45) clinical samples belonging to treatment-experienced patients were analyzed using ViroSeq (VS) Genotyping Software v3.0.0.32.
• All (VS) results were compared to the FDAregistered DPM product and to the RUO ViroScore-HIV® system; both products from Advanced Biological Laboratories
• ViroScore® include several knowledge databases i.e. Stanford HIVdb v7.0.1 (SD) or the virtualphenotypic-based algorithm from Geno2Pheno v3.3 (G2P) - Fig. 1 .
Results
Conclusions
• Laboratories performing DR testing should be aware of alternative interpretive systems which could be used to supplement their existing DR reports. • When considering only the interpretations where SD was in agreement with G2P (714), VS reported 1-level lower resistance values for at least one drug in 12.2% of the samples - Fig. 3. • At the drug level, differences were observed as shown in Fig. 4 . 
